SCHEMBL7014052

SCHEMBL7014052

Cn1cc(-c2cn(C(=O)OC(C)(C)C)c(=O)n2-c2cn(CCCCN3C(=O)c4ccccc4C3=O)c3ccccc23)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 3/20 0.41
CDK9 P50750 3/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
PRKCA P17252 2/20 0.37
PRKCG P05129 1/20 0.37
PRKCB P05771 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCD Q05655 1/20 0.37
PIM1 P11309 3/20 0.37
MARK3 P27448 1/20 0.37
MAP4K2 Q12851 1/20 0.37
CAMK2B Q13554 1/20 0.37
PIM3 Q86V86 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
CAMK2D Q13557 2/20 0.36
GSK3B P49841 1/20 0.36
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6980500 0.80 CCNT1 (0.41) CCNT1CDK9CCNA2CDK2PRKCA
SCHEMBL7013228 0.78 PIM1 (0.42) CCNT1CDK9CDK2PRKCAPRKCG
SCHEMBL7005341 0.76 PIM1 (0.45) CCNT1CDK9CDK2PRKCAPRKCG
SCHEMBL7009411 0.69 ALDH1A1 (0.41) CCNT1CDK9PIM1CAMK2DGSK3B
SCHEMBL7007071 0.66 CAMK2D (0.47) CAMK2DBRD4
SCHEMBL7007161 0.66 CAMK2D (0.57) CCNT1CDK9PRKCAPIM1CAMK2D
Trifluoroacetic Acid SCHEMBL7007891 0.66 CAMK2D (0.49) CCNT1CDK9CCNA2CDK2PRKCA
SCHEMBL6978208 0.65 CNR1 (0.40) CCNT1CDK9CCNA2CDK2
SCHEMBL6981336 0.64 CCNT1 (0.42) CCNT1CDK9CCNA2CDK2CAMK2D
SCHEMBL8837853 0.64 SMN1; SMN2 (0.60) CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030134886-A1 Pharmaceutically active compounds ASTRAZENECA AB, A SWEDISH CORPORATION 2003-07-17 US disclosed
EP-1042317-B1 Indole derivatives as PKC-inhiboitors ASTRAZENECA AB (SE) 2003-05-14 EP disclosed
US-6492409-B1 SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS ASTRAZENECA AB (SE) 2002-12-10 US disclosed
US-6337342-B1 ARYLIMIDAZOLONE DERIVATIVES ASTRAZENECA AB (SE) 2002-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134886-A1 Pharmaceutically active compounds HTR3C, HTR6, CNR1 CCNT1 354/4885CDK9 969/4885CCNA2 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.